Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is affecting different regions of the world since the end of 2019, causing infection named COVID-19 by World Health Organization (WHO). Up to the date (i.e. April 28, 2020) 3,063,814 cases have been confirmed by the Center for System Science and Engineering (CSSE) at Johns Hopkins University (JHU) (https://coronavirus.jhu.edu/map. html). The infection may produce, after a period of cough, fever and thoracic pain, a severe pulmonary failure requiring in more than 15% of the patients assisted ventilation (Zhou et al., 2020). Due to the lack of specific therapy and vaccine, the consequences of hospitals overload have produced a dangerous growth of the number of deaths. Sars-CoV-2 and Sars-CoV, responsible of the outbreak in 2003, share a high homology in the structure of spike protein, which bind host cells receptor (Zhang et al., 2020). Angiotensin-converting enzyme 2 (ACE2) is the host functional receptor recognized by viral protein (spike) and allows to the Sars-CoV-2 to go into the cell (Hoffmann et al., 2020). The affinity to bind ACE2 receptor is documented as more efficiently for Sars-CoV-2 than his predecessor, explaining the higher rate of transmission. The expression of ACE2 is ubiquitous, although lung represents the target and more vulnerable organ due to the high presence of ACE2 on the type II alveolar epithelial cell allowing adhesion, translocation and facilitating replication. However, different tissues such as gastrointestinal tract and heart among others, representing a further possible entry site, may be hit by Sars-CoV-2, characterizing the clinical picture for extra-pulmonary manifestations (Zhang et al., 2020; Zheng et al., 2020; Gu et al., 2020). Moreover, the different molecular expression of ACE2, limiting the ingress of Sars-CoV-2 into the cells, seems to be crucial to track the incidence of COVID-19 in different populations and to explain their dissimilar susceptibility. Regarding the potential racial heterogeneous molecular expression of ACE2, first Zhao et al. (Zhao et al., 2020) have analyzed lung cells through single-cell RNA sequencing (scRNA-Seq) and have interestingly found higher ACE2 pulmonary levels in Asian than white and African American donors. Additional studies in literature, analyzing big datasets such as the cancer genome atlas (TCGA), have not confirmed this evidence, indicating a similar molecular expression of ACE2 in the lung cells, without difference of race (Chen et al., 2020; Cai, 2020). Evidences result controversial, although recently has been documented the highest expression of ACE2 in the upper respiratory tract, particularly in the nasal epithelial cells, explaining a possible lack in the previous studies limited only to analysis of lung tissue (Sungnak et al., 2020). However, focusing on black population, a reduced molecular